| 1 |
30127933 | Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand. | 2018 Sep |
3 |
| 2 |
24345465 | Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. | 2014 Mar |
2 |
| 3 |
24927258 | Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade. | 2014 |
2 |
| 4 |
23387208 | [Arsenic trioxide enhances TRAIL inducing human lung cancer cell line A549 cells apoptosis by down-regulate the expression of NF-kappaB]. | 2012 Nov |
2 |
| 5 |
20953137 | Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. | 2010 Dec 1 |
4 |
| 6 |
18172319 | Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. | 2008 Jan 1 |
3 |
| 7 |
16434995 | TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. | 2006 Feb 13 |
4 |
| 8 |
14726646 | Arsenic trioxide and paclitaxel induce apoptosis by different mechanisms. | 2004 Mar |
1 |
| 9 |
15634594 | [Biologic changes in MDS-L cell line induced by As2O3 and/or TRAIL]. | 2004 Oct |
2 |
| 10 |
12531793 | Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. | 2003 May 15 |
1 |
| 11 |
26680977 | Effect of Arsenic Trioxide in TRAIL (Tumor Necrosis Factor-related Apoptosis Inducing Ligand)-Mediated Apoptosis in Multiple Myeloma Cell Lines. | 2003 Dec |
8 |